4.7 Article

Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 14, Pages 7817-7826

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00596

Keywords

-

Funding

  1. 2017 AACR-Bayer Innovation and Discovery grant [17-80-44-GRAY]
  2. DF/HCC GI SPORE Developmental Research Project Award [P50CA127003]
  3. Hale Center for Pancreatic Research
  4. American Cancer Society [132205-RSG-18-039-01-DMC]
  5. Welch Foundation [I1829]
  6. NIH [5U01CA207160]

Ask authors/readers for more resources

Doublecortin-like kinase 1 (DCLK1) is a serine/threonine kinase that is overexpressed in gastrointestinal cancers, including esophageal, gastric, colorectal, and pancreatic cancers. DCLK1 is also used as a marker of tuft cells, which regulate type II immunity in the gut. However, the substrates and functions of DCLK1 are understudied. We recently described the first selective DCLK1/2 inhibitor, DCLK1-IN-1, developed to aid the functional characterization of this important kinase. Here we describe the synthesis and structure-activity relationships of 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one DCLK1 inhibitors, resulting in the identification of DCLK1-IN-1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available